10 Apr 2019
Notice for Yellow Fever Vaccination Centres: Leaving the EU – yellow fever vaccine supplyNaTHNaC receives reassurance that contingencies for continuous yellow fever vaccine supply to the UK are robust and sustainable in the event of a ‘no deal’ EU Exit
On behalf of Yellow Fever Vaccination Centres (YFVC) in England, Wales and Northern Ireland, NaTHNaC has been working closely with Sanofi Pasteur who manufacture, pack and supply yellow fever vaccine in France for the UK market. Sanofi Pasteur advises that their contingency plan for a ‘no deal’ EU Exit includes increasing yellow fever vaccine stock levels and securing alternative and robust supply lines into the UK.
Local stockpiling is unnecessary and YFVC should continue to order YF vaccine as usual.
Further updates will be provided when available.
- Department of Health and Social Care. Update on medicines and medical products supply as we exit the EU. 25 February 2019
- Department of Health and Social Care Update: Written statement - HCWS1358 25 February 2019
- Medicines and Healthcare Regulatory Agency (MHRA). Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal. 29 February 2019